Abstract
Background: CD47 is a receptor widely expressed in human tumors, including lymphoma, AML, and many solid tumors. It interacts with its ligand SIRPα on macrophages, also found on dendric cells, to evade macrophage phagocytosis. CD47 is an important innate and adaptive immune checkpoint and is considered one of the most promising immuno-oncology targets since PD-1/PDL-1. Anti-CD47 antibodies and SIRPα fusion proteins are currently being developed for the treatment of various cancers. It is believed that CD47 expression on the surface of cancer cells is critical to the success of these therapies and if true, CD47 could become a predictive biomarker for the treatment of cancer and/or be developed as a companion diagnostic (CDx).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
